ERBB2 and breast carcinoma: The results of the current DESTINY-Breast01 and DESTINY-Breast03 studies show that trastuzumab deruxtecan significantly prolongs survival in patients with brain metastases from breast cancer for multiple lines of therapy beyond the second line in advanced HER2-positive breast cancer, especially in patients with advanced breast cancer who have failed multiple lines of therapy.